Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Caladrius Biosciences stock | $1.11

Learn how to easily invest in Caladrius Biosciences stock.

Caladrius Biosciences Inc is a biotechnology business based in the US. Caladrius Biosciences shares (CLBS) are listed on the NASDAQ and all prices are listed in US Dollars. Caladrius Biosciences employs 24 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Caladrius Biosciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLBS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Caladrius Biosciences stock price (NASDAQ: CLBS)

Use our graph to track the performance of CLBS stocks over time.

Caladrius Biosciences shares at a glance

Information last updated 2021-10-24.
Latest market close$1.11
52-week range$1.11 - $3.05
50-day moving average $1.20
200-day moving average $1.40
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.70

Buy Caladrius Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Caladrius Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Caladrius Biosciences price performance over time

Historical closes compared with the close of $1.11 from 2021-10-26

1 week (2021-10-20) -5.13%
1 month (2021-09-27) -8.26%
3 months (2021-07-27) -17.78%
6 months (2021-04-27) -32.73%
1 year (2020-10-27) -30.19%
2 years (2019-10-25) -48.37%
3 years (2018-10-26) 4.32
5 years (2016-10-27) 4.1201

Caladrius Biosciences financials

Gross profit TTM $0
Return on assets TTM -22.27%
Return on equity TTM -35.45%
Profit margin 0%
Book value $1.76
Market capitalisation $66.7 million

TTM: trailing 12 months

Shorting Caladrius Biosciences shares

There are currently 1.3 million Caladrius Biosciences shares held short by investors – that's known as Caladrius Biosciences's "short interest". This figure is 15.2% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Caladrius Biosciences shares can be evaluated.

Caladrius Biosciences's "short interest ratio" (SIR)

Caladrius Biosciences's "short interest ratio" (SIR) is the quantity of Caladrius Biosciences shares currently shorted divided by the average quantity of Caladrius Biosciences shares traded daily (recently around 253576.15384615). Caladrius Biosciences's SIR currently stands at 5.2. In other words for every 100,000 Caladrius Biosciences shares traded daily on the market, roughly 5200 shares are currently held short.

However Caladrius Biosciences's short interest can also be evaluated against the total number of Caladrius Biosciences shares, or, against the total number of tradable Caladrius Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Caladrius Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Caladrius Biosciences shares in existence, roughly 20 shares are currently held short) or 0.0224% of the tradable shares (for every 100,000 tradable Caladrius Biosciences shares, roughly 22 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Caladrius Biosciences.

Find out more about how you can short Caladrius Biosciences stock.

Caladrius Biosciences share dividends

We're not expecting Caladrius Biosciences to pay a dividend over the next 12 months.

Have Caladrius Biosciences's shares ever split?

Caladrius Biosciences's shares were split on a 1:10 basis on 27 July 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Caladrius Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Caladrius Biosciences shares which in turn could have impacted Caladrius Biosciences's share price.

Caladrius Biosciences share price volatility

Over the last 12 months, Caladrius Biosciences's shares have ranged in value from as little as $1.11 up to $3.05. A popular way to gauge a stock's volatility is its "beta".

CLBS.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caladrius Biosciences's is 1.045. This would suggest that Caladrius Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Caladrius Biosciences overview

Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc.

Frequently asked questions

What percentage of Caladrius Biosciences is owned by insiders or institutions?
Currently 3.62% of Caladrius Biosciences shares are held by insiders and 28.481% by institutions.
How many people work for Caladrius Biosciences?
Latest data suggests 24 work at Caladrius Biosciences.
When does the fiscal year end for Caladrius Biosciences?
Caladrius Biosciences's fiscal year ends in December.
Where is Caladrius Biosciences based?
Caladrius Biosciences's address is: 110 Allen Road, Basking Ridge, NJ, United States, 07920
What is Caladrius Biosciences's ISIN number?
Caladrius Biosciences's international securities identification number is: US1280582032
What is Caladrius Biosciences's CUSIP number?
Caladrius Biosciences's Committee on Uniform Securities Identification Procedures number is: 128058104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site